Smoore Announces Equity Incentive Plan: Grants Over 4M Shares to 49 Employees, Valued at Over HK$54.14M

May.08
Smoore Announces Equity Incentive Plan: Grants Over 4M Shares to 49 Employees, Valued at Over HK$54.14M
Smoore International has granted a total of 4.004 million shares to 49 employees under its share award and option plans. The package includes 1.614 million awarded shares and 2.39 million options exercisable at HK$13.52 per share, with a total value of HK$54.14 million.

On May 7, 2025, Smoore International Holdings Limited (HKEX: 6969) issued two announcements, declaring that it has granted stock awards and stock options to multiple key employees under the company's stock award plan and stock option plan, with an exercise price of HK$13.52 per share based on the closing price of the company's stock on the day of grant. The total amount of the award plan can reach HK$54.14 million.

 

The announcement stated that the company granted a total of 1,614,000 shares of bonus stock to 36 eligible participants (all of whom are employees of the group). The grant price for these bonus shares was zero, while the closing price of the company's stock on the day of grant was HK$13.52 per share.

 

Smoore Announces Equity Incentive Plan: Grants Over 4M Shares to 49 Employees, Valued at Over HK$54.14M
Announcement Document | Image Source: Smoore International

 

The vesting period for these stock rewards is set between May 7, 2026 and May 7, 2029. The company stated that the number of shares granted to each recipient is based on their position, tenure, and performance evaluation results.

 

After this round of awards, according to the stock award plan, there are still 307,546,059 shares available for future grants.

 

In addition, on the same day, Smoore International also granted a total of 2,390,000 stock options to 13 eligible participants (all of whom are employees of the group) under the revised first public offering stock option plan.

 

Smoore Announces Equity Incentive Plan: Grants Over 4M Shares to 49 Employees, Valued at Over HK$54.14M
Notice document | Image source: Smoore International

 

The exercise price for these stock options is set at HK$13.52 per share. The options are valid for a period of 10 years from the date of issuance, expiring on May 6, 2035. The vesting period for the options is from May 7, 2026 to May 7, 2029, and the specific exercise periods for different batches of options vary, with the latest exercise date being May 6, 2035. Similar to stock awards, the number of stock options granted is tied to the individual's rank, tenure, and performance evaluation results.

 

After this equity purchase, a total of 554,727,627 shares will be available for future grants based on the authorized limit of the equity purchase plan.

 

The company emphasized that the issuance of stock awards and stock options in this round must be accepted by the recipients before they can take effect, and are subject to clawback provisions outlined in each respective plan. Specifically, if the recipients terminate their employment, any unvested stock awards and stock options will be forfeited. The company's board of directors believes that these incentive measures will help boost employee motivation and cohesion, ultimately fostering continuous growth and value creation for the company.

 

According to the listing rules, the issuance does not require approval from the company's shareholders. The company also confirms that the recipients of the issuance are not directors, senior executives, major shareholders, or their affiliates.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Malaysia MRECA Urges Inclusive, Evidence-Based Consultation on Vape Regulations, Rejects Blanket Ban
Malaysia MRECA Urges Inclusive, Evidence-Based Consultation on Vape Regulations, Rejects Blanket Ban
The Malaysia Retail Electronic Cigarette Association (MRECA) criticized a Health Parliament Special Select Committee (PSSC) report recommending a blanket ban on e-cigarettes, saying it excluded key stakeholders and relied on unverified claims. MRECA called for transparent, science-based consultations and affirmed support for balanced regulation covering age limits, product standards, and consumer safety.
Sep.10
Yekaterinburg shuts down illegal e-cigarette oil factory; Russia plans to ban e-cigarette sales
Yekaterinburg shuts down illegal e-cigarette oil factory; Russia plans to ban e-cigarette sales
An illegal e-cigarette oil factory was shut down in Yekaterinburg, Russia. The illegal e-cigarette oil was produced under unsanitary conditions, with falsified addresses and production dates on product labels. Some of the employees were hearing-impaired. The Russian government plans a complete ban on e-cigarette sales, which has received support from the president.
Sep.30 by 2FIRSTS.ai
Spanish Anti-Tobacco Group Urges 10-Year “Cooling-Off” Ban on Ex-Officials Working for Tobacco Industry
Spanish Anti-Tobacco Group Urges 10-Year “Cooling-Off” Ban on Ex-Officials Working for Tobacco Industry
Spanish advocacy group Nofumadores.org has called for urgent reforms to Spain’s conflict-of-interest rules to bar politicians and senior civil servants from taking jobs in the tobacco industry for 10 years after leaving office. The appeal follows a series of hires by Philip Morris, Japan Tobacco International (JTI) and distributor Logista that the group says risk undermining ongoing anti-tobacco legislation. The Health Ministry, led by Mónica García, aims to expand smoke-free spaces, raise tobac
Sep.08
Yinghe Technology's Sikary reports revenue of 1.274 billion yuan in 2025 first half, with net profit of 3.20 billion yuan
Yinghe Technology's Sikary reports revenue of 1.274 billion yuan in 2025 first half, with net profit of 3.20 billion yuan
Yinghe Technology's subsidiary Sikary reports 12.74 billion yuan in revenue and 3.20 billion yuan in net profit.
Aug.25 by 2FIRSTS.ai
Company|BAT Invests in Expansion of Italian Factory, Adding 16 Production Lines for Heated Tobacco and Nicotine Pouches
Company|BAT Invests in Expansion of Italian Factory, Adding 16 Production Lines for Heated Tobacco and Nicotine Pouches
BAT Italy will expand its Trieste plant, adding 16 new production lines for heated tobacco cartridges, nicotine pouches, and nicotine replacement therapy products. The expansion adds 6,300 m² of space, bringing the total to 30,000 m². This is part of BAT’s €500 million five-year investment plan launched in 2023.
Sep.15 by 2FIRSTS.ai
Singapore to Classify Etomidate as Class C Drug from September; Importers and Sellers Face Up to 20 Years in Prison
Singapore to Classify Etomidate as Class C Drug from September; Importers and Sellers Face Up to 20 Years in Prison
Singapore will classify the anesthetic etomidate as a Class C drug from September 1, with traffickers and users facing prosecution and a minimum one-year jail term. The move comes amid growing concerns over the health risks posed by etomidate-laced e-cigarettes, which have become increasingly popular. The government has stepped up enforcement efforts, seizing over 850 e-cigarettes in recent operations.
Aug.25 by 2FIRSTS.ai